Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | CETP | P11597 | 6/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14668817 | 0.86 | CHRM2 (0.44) | CHRM2CHRM1CHRM3CETPNR1H2 | |
| SCHEMBL29153076 | 0.85 | CHRM2 (0.66) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL17187734 | 0.85 | CHRM2 (0.66) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL29964794 | 0.85 | CHRM2 (0.66) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL9311803 | 0.85 | CHRM2 (0.66) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL23807839 | 0.85 | CHRM2 (0.66) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL21317463 | 0.85 | CHRM2 (0.51) | CHRM2CHRM1CHRM3CETPNR1H2 | |
| SCHEMBL13845643 | 0.84 | CHRM2 (0.42) | CHRM2CHRM1CHRM3CETPNR1H2 | |
| SCHEMBL30501783 | 0.83 | CHRM2 (0.49) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL14047316 | 0.82 | NR1H2 (0.51) | CHRM2CHRM1CHRM3CETPNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091482-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190308973-A1 | ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS | ARDELYX, INC. | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091482-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | FXR1, FXR2, NR1H4 | CHRM2 1180/4885CHRM1 492/4885CHRM3 1795/4885 |
| US-20190308973-A1 | ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS | FXR1, FXR2, NR1H4 | CHRM2 1180/4885CHRM1 492/4885CHRM3 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.